Abstract
A novel series of quinoline benzamide derivatives have been synthesized and screened for their anticancer activity against a breast cancer cell line (MDA-MB-231) by MTT assay method. All the synthesized compounds were confirmed by spectral characterization viz. FTIR, 1H & 13C NMR and MS. All the molecules demonstrated potency less than 35 μM and were better than standard cisplatin but not comparable to doxorubicin. Compound 3i (IC50 = 6.86 μM) exhibited better promising anti-breast cancer activity among various synthesized molecules and in addition, docking of compound 3i into kinesin spindle protein (KSP) active site was performed in order to predict the affinity and the orientation at the enzyme active site.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
